Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hongfu, Xu, Baohua, Li, Na, Zheng, Bin, Zheng, Zhiwei, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/
https://www.ncbi.nlm.nih.gov/pubmed/34867339
http://dx.doi.org/10.3389/fphar.2021.732912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/
https://www.ncbi.nlm.nih.gov/pubmed/34867339
http://dx.doi.org/10.3389/fphar.2021.732912

Ejemplares similares